Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

INTRODUCTION: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. METHODS: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced malignancies. ALTA randomized patients with crizotinib-refr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gettinger, Scott N., Huber, Rudolf M., Kim, Dong-Wan, Bazhenova, Lyudmila, Hansen, Karin Holmskov, Tiseo, Marcello, Langer, Corey J., Paz-Ares Rodríguez, Luis G., West, Howard L., Reckamp, Karen L., Weiss, Glen J., Smit, Egbert F., Hochmair, Maximilian J., Kim, Sang-We, Ahn, Myung-Ju, Kim, Edward S., Groen, Harry J.M., Pye, Joanna, Liu, Yuyin, Zhang, Pingkuan, Vranceanu, Florin, Camidge, D. Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440305/
https://www.ncbi.nlm.nih.gov/pubmed/36065449
http://dx.doi.org/10.1016/j.jtocrr.2022.100385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440305/
https://www.ncbi.nlm.nih.gov/pubmed/36065449
http://dx.doi.org/10.1016/j.jtocrr.2022.100385

Ejemplares similares